Get the Stockscreener App
5.96
0.83%
-0.05
After Hours:
5.96
Nuvectis Pharma Inc stock is traded at $5.96, with a volume of 144.99K.
It is down -0.83% in the last 24 hours and down -5.10% over the past month.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
See More
Previous Close:
$6.01
Open:
$5.98
24h Volume:
144.99K
Relative Volume:
1.42
Market Cap:
$151.72M
Revenue:
-
Net Income/Loss:
$-22.38M
P/E Ratio:
-4.227
EPS:
-1.41
Net Cash Flow:
$-15.54M
1W Performance:
-0.75%
1M Performance:
-5.10%
6M Performance:
-30.09%
1Y Performance:
-3.72%
1-Day Range:
$5.85
$6.1371
1-Week Range:
$5.85
$6.30
52-Week Range:
$4.44
$11.80
Nuvectis Pharma Inc Stock (NVCT) Company Profile
Name
Nuvectis Pharma Inc
Sector
Industry
Phone
360-837-7232
Address
1 BRIDGE PLAZA, SUITE 275, FORT LEE
Compare NVCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVCT
Nuvectis Pharma Inc
|
5.96 | 153.00M | 0 | -22.38M | -15.54M | -1.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-25 | Initiated | Maxim Group | Buy |
| Mar-17-25 | Initiated | Laidlaw | Buy |
| Jul-13-22 | Initiated | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc Stock (NVCT) Latest News
Technical analysis overview for Nuvectis Pharma Inc. stockJuly 2025 Fed Impact & Consistent Profit Trading Strategies - newser.com
Nuvectis Pharma (NASDAQ:NVCT) Given Sell (E+) Rating at Weiss Ratings - MarketBeat
Using flow based indicators on Nuvectis Pharma Inc.Oil Prices & Long-Term Growth Stock Strategies - newser.com
Applying Wyckoff theory to Nuvectis Pharma Inc. stockNew Guidance & Smart Allocation Stock Reports - newser.com
Published on: 2025-10-05 01:41:39 - newser.com
Price momentum metrics for Nuvectis Pharma Inc. explained2025 Key Lessons & Weekly Top Stock Performers List - newser.com
Using economic indicators to assess Nuvectis Pharma Inc. potential2025 Performance Recap & AI Powered Buy and Sell Recommendations - newser.com
How to use Fibonacci retracement on Nuvectis Pharma Inc.Market Growth Review & Low Drawdown Investment Ideas - newser.com
Momentum divergence signals in Nuvectis Pharma Inc. chartJuly 2025 Recap & Expert Approved Momentum Trade Ideas - newser.com
Using portfolio simulators with Nuvectis Pharma Inc. includedEarnings Growth Summary & Long-Term Safe Return Strategies - newser.com
Nuvectis Pharma Inc Stock Analysis and ForecastMarket Rumors and News & Market Trend Real-Time Reports - earlytimes.in
Goldman Sachs Group Inc. Takes $446,000 Position in Nuvectis Pharma, Inc. $NVCT - MarketBeat
What drives Nuvectis Pharma Inc stock priceTrading Volume Trends & Small Budget Trading Ideas - Early Times
Nuvectis Pharma (NASDAQ:NVCT) Shares Up 2.2%Time to Buy? - MarketBeat
Nuvectis Pharma (NASDAQ:NVCT) Shares Up 2.2% – Time to Buy? - Defense World
Nuvectis Pharma Appoints Juan Sanchez to Board - The Globe and Mail
Nuvectis Pharma adds former Intra-Cellular exec to board of directors - Investing.com Nigeria
Nuvectis Pharma adds former Intra-Cellular exec to board of directors By Investing.com - Investing.com South Africa
Nuvectis Pharma Appoints Juan Sanchez, MD, To Board - citybiz
Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors - GlobeNewswire
From $14.6B J&J Deal Success: Nuvectis Pharma Adds Key Biotech Executive to Board Ahead of Phase 1b Trial - Stock Titan
Is Nuvectis Pharma Inc. forming a reversal pattern2025 Pullback Review & Short-Term Trading Opportunity Alerts - newser.com
Nuvectis Pharma Inc Stock (NVCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nuvectis Pharma Inc Stock (NVCT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mosseri Marlio Charles | 10% Owner |
Jun 18 '25 |
Buy |
8.05 |
28,043 |
225,746 |
2,976,203 |
| Mosseri Marlio Charles | 10% Owner |
Jun 17 '25 |
Buy |
8.11 |
5,399 |
43,786 |
2,948,160 |
| Mosseri Marlio Charles | 10% Owner |
May 12 '25 |
Buy |
8.11 |
21,167 |
171,664 |
2,942,761 |
| Mosseri Marlio Charles | 10% Owner |
May 06 '25 |
Buy |
8.59 |
12,444 |
106,955 |
2,896,565 |
| Mosseri Marlio Charles | 10% Owner |
May 07 '25 |
Buy |
8.59 |
12,317 |
105,770 |
2,908,882 |
| Mosseri Marlio Charles | 10% Owner |
May 08 '25 |
Buy |
8.65 |
2,650 |
22,922 |
2,911,532 |
| Mosseri Marlio Charles | 10% Owner |
Feb 07 '25 |
Buy |
5.00 |
240,000 |
1,200,000 |
2,884,121 |
| BENTSUR RON | Chairman & CEO |
Dec 24 '24 |
Buy |
4.65 |
4,500 |
20,925 |
3,270,924 |
| Mosseri Marlio Charles | 10% Owner |
Dec 13 '24 |
Buy |
4.70 |
17,000 |
79,900 |
2,612,000 |
| Poradosu Enrique | Chief Science & Business Off |
Nov 19 '24 |
Buy |
4.99 |
2,000 |
9,980 |
1,506,319 |
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):